Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of HTL0018318 in healthy volunteers
NL-OMON26350Phase 1Active, not recruiting
- Sponsor
- Heptares Therapeutics
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HTL0018318 in Alzheimer's disease (AD) and schizophrenia (3 arms), sponsored by Heptares Therapeutics. Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started Nov 2015; status: active, not recruiting.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NL-OMON26350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26350.